

**EISAI TO ACQUIRE CHINESE GENERIC PHARMACEUTICAL COMPANY
LIAONING TIANYI BIOLOGICAL PHARMACEUTICAL CO., LTD.**
*STRENGTHENING BUSINESS PLATFORM IN CHINA
TO ADDRESS DIVERSE MEDICAL NEEDS*

further growth. Eisai will continue to further contribute to increasing the benefits for a greater number of patients and their families throughout China.

In addition, the signing of this agreement will have a minor impact on the consolidated result forecasts for the period ended March 31, 2016.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

[Notes to editors]

1. About Liaoning TianYi Biological Pharmaceutical Co., Ltd.

Company Name	Liaoning TianYi Biological Pharmaceutical Co., Ltd.
Location	Benxi, Liaoning Province, China
Date Established	December, 2011

3. About Eisai's China Pharmaceutical Business

Eisai's business in China has a history spanning almost 25 years. Eisai entered the China market in 1991 through a joint venture company, and in 1996 established Eisai China Inc., a 100% wholly owned subsidiary which has manufacturing and marketing functions. Furthermore, Eisai established Eisai (Suzhou) Trading Co., Ltd. in 2010 to directly import and trade licensed products, and continues to expand business from a local base. In December 2014, Eisai newly established Eisai China Holdings Ltd. as a holding company in China to manage these two companies. By doing so, an autonomous management structure was established to enable quick decision making in China.

Through this acquisition, Eisai will enter the generic pharmaceutical business in China in addition to expanding its existing business focused on new medicines. After the execution of the agreement, the trading name of Liaoning TianYi Biological Pharmaceutical Co., Ltd. will be changed to Eisai (Liaoning) Pharmaceutical Co., Ltd., and the company will be made a subsidiary of Eisai China Holdings Ltd.

¹ ©2015 IMS Health, IMS World Review Executive 2015